We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
-9.61%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$2.31B
AUM Growth
-$535M
Cap. Flow
-$185M
Cap. Flow %
-8.02%
Top 10 Hldgs %
64.82%
Holding
66
New
3
Increased
1
Reduced
14
Closed
7

Top Buys

Rank Stock Value
1
IMPL
Impel Pharmaceuticals Inc. Common Stock
IMPL
+$34.4M
2
VALN
Valneva
VALN
+$11M
3
ELEV
Elevation Oncology
ELEV
+$6.14M
4
MRUS
Merus
MRUS
+$5.9M

Top Sells

Rank Stock Value
1
LEGN icon
Legend Biotech
LEGN
+$61.1M
2
AMRS
Amyris Inc.
AMRS
+$22.7M
3
AKRO
Akero Therapeutics
AKRO
+$19.5M
4
ASND icon
Ascendis Pharma A/S
ASND
+$18.4M
5
EPIX
ESSA Pharma
EPIX
+$15M

Sector Composition

Rank Sector Weight
1 Healthcare 84.84%
2 Materials 8.25%
3 Financials 6.91%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TIL icon
1
Instil Bio
TIL
$49.4M
$241M 10.44%
624,339
– –
ALXO icon
2
ALX Oncology
ALXO
$268M
$231M 9.99%
4,220,048
– –
ASND icon
3
Ascendis Pharma A/S
ASND
$16.7B
$201M 8.69%
1,526,359
-137,883
-8% -$18.4M
AMRS
4
DELISTED
Amyris Inc.
AMRS
$191M 8.25%
11,639,929
-1,521,918
-12% -$22.7M
NFH
5
DELISTED
New Frontier Health Corporation Ordinary Shares
NFH
$160M 6.91%
14,300,000
– –
HRMY icon
6
Harmony Biosciences
HRMY
$2.07B
$128M 5.54%
4,534,341
– –
GTH
7
DELISTED
Genetron Holdings Limited ADS
GTH
$128M 5.53%
2,113,287
– –
TARS icon
8
Tarsus Pharmaceuticals
TARS
$2.57B
$86.6M 3.75%
2,987,331
-257,704
-8% -$8.05M
ALGS icon
9
Aligos Therapeutics
ALGS
$26.3M
$72.3M 3.13%
141,881
– –
BOLT icon
10
Bolt Biotherapeutics
BOLT
$7.72M
$59.9M 2.59%
193,565
– –
KALV
11
DELISTED
KalVista Pharmaceuticals
KALV
$44.6M 1.93%
1,863,296
– –
EPIX
12
DELISTED
ESSA Pharma
EPIX
$44.3M 1.92%
1,551,680
-517,227
-25% -$15M
LEGN icon
13
Legend Biotech
LEGN
$3.68B
$39.3M 1.7%
956,702
-1,798,305
-65% -$61.1M
SVA
14
DELISTED
Sinovac Biotech, Ltd
SVA
$38.2M 1.65%
5,900,000
– –
ISEE
15
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$37.6M 1.63%
5,966,527
– –
SRRA
16
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$37.3M 1.62%
1,917,074
– –
OLMA icon
17
Olema Pharmaceuticals
OLMA
$1.01B
$34.7M 1.5%
1,238,575
– –
CRNX icon
18
Crinetics Pharmaceuticals
CRNX
$8.88B
$33M 1.43%
1,752,346
-461,792
-21% -$8.11M
TERN
19
DELISTED
Terns Pharmaceuticals
TERN
$32.8M 1.42%
2,675,133
– –
CLDX icon
20
Celldex Therapeutics
CLDX
$2.79B
$32.4M 1.4%
968,906
-322,969
-25% -$8.87M
ZLAB icon
21
Zai Lab
ZLAB
$2.1B
$31M 1.34%
175,000
– –
IMPL
22
DELISTED
Impel Pharmaceuticals Inc. Common Stock
IMPL
$25.5M 1.11%
+2,884,789
New +$34.4M
ACRS icon
23
Aclaris Therapeutics
ACRS
$744M
$24.1M 1.04%
1,374,279
-272,935
-17% -$6.2M
KDMN
24
DELISTED
Kadmon Holdings, Inc.
KDMN
$22.5M 0.97%
5,817,459
– –
VRNA
25
DELISTED
Verona Pharma
VRNA
$19.9M 0.86%
3,048,507
– –
1
2 3

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
GP
Guardian Partners Toronto, Canada $1.2B AUM 35.94% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
CA
Callahan Advisors Houston, Texas $1.2B AUM 22.34% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
HCM
Hodges Capital Management Dallas, Texas $1.21B AUM 49% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.21B AUM

Vivo Capital's Q2 2021 Portfolio in Review

As of Q2 2021, Vivo Capital held 66 positions worth $2.31B, down 19% from $2.85B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Vivo Capital withdrew a net $185M in Q2 2021, closing 7 positions and reducing 14 holdings. Its most notable exit was Akero Therapeutics, an estimated $19.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 85% a quarter earlier, followed by Materials and Financials.

Against the trend, Vivo Capital opened a new position in Impel Pharmaceuticals Inc. Common Stock worth $25.5M.

  • Vivo Capital's largest Q2 2021 buy was Impel Pharmaceuticals Inc. Common Stock: 2,884,789 shares worth $25.5M.
  • Vivo Capital added most to Merus in Q2 2021, an estimated $5.9M increase.
  • Vivo Capital's biggest Q2 2021 reduction was Legend Biotech, cutting an estimated $61.1M.
  • Vivo Capital fully exited Akero Therapeutics in Q2 2021, selling an estimated $19.5M.
  • Vivo Capital's ten largest holdings make up 65% of its $2.31B portfolio in Q2 2021.
  • Vivo Capital opened 3 new positions and closed 7 in Q2 2021.
  • Vivo Capital's portfolio value fell 19% quarter-over-quarter to $2.31B.

Based on Vivo Capital's 13F filing for Q2 2021, filed 16 Aug 2021.